Topical microRNA-195 formulation for diabetic retinopathy treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic retinopathy, such as intra-ocular injections of anti-VEGF drugs, have limitations in effectively addressing the underlying blood vessel permeability and edema issues, and there is a need for alternative methods that can provide neuroprotective effects and reduce inflammation.
Innovation Solution
A topical ophthalmic formulation of microRNA-195, packaged in various delivery systems like liposomes, nanoparticles, and conjugates, is developed for direct application to the eye, which can suppress sema3A expression and promote neuroprotective effects, reducing blood vessel permeability and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intra-ocular injection of anti-VEGF drugs is used to treat diabetic retinopathy, then blood vessel formation is suppressed, but the treatment does not effectively address underlying blood vessel permeability and edema issues
Solution Approach 1:
The patent uses microRNA-195 as an intermediary molecule that mediates the suppression of sema3A expression, thereby addressing blood vessel permeability and edema. This molecular mediator provides a more comprehensive treatment mechanism compared to direct anti-VEGF injection, resolving the contradiction between treatment effectiveness and mechanism complexity by introducing a biologically specific intermediary that targets the root cause.
Solution Approach 2:
The patent changes the therapeutic parameter from suppressing VEGF (anti-VEGF drugs) to suppressing sema3A (microRNA-195). This parameter change addresses the limitation of anti-VEGF treatments by targeting a different molecular pathway (sema3A-mediated blood vessel permeability) that is not effectively addressed by VEGF suppression alone, thereby improving overall treatment effectiveness.
2Object-affected harmful factors
If topical ophthalmic formulation is used instead of intra-ocular injection, then delivery safety is improved, but drug delivery efficiency may be reduced
Solution Approach 1:
The patent employs liposomal encapsulation as a flexible shell structure to protect and deliver microRNA-195 topically. The liposomal shell enables the formulation to be applied as eye drops while protecting the microRNA from degradation and facilitating penetration into ocular tissues, thereby maintaining delivery efficiency while eliminating injection-related side effects.
Solution Approach 2:
The liposome acts as an intermediary carrier that facilitates the transfer of microRNA-195 from the topical application site to the target tissues. This intermediary structure solves the contradiction by enabling efficient drug delivery through a safe topical route, combining the benefits of both approaches.
3Stability of the object's composition
If microRNA-195 is packaged in delivery systems like liposomes or nanoparticles, then delivery stability is improved, but formulation complexity increases
Solution Approach 1:
The patent uses liposomal encapsulation with phospholipid bilayer membranes to protect microRNA-195 from degradation. This flexible shell structure provides excellent stability while maintaining a relatively simple formulation structure that can be manufactured and administered practically, resolving the contradiction between stability and complexity.
Solution Approach 2:
The formulation uses composite structures combining lipids, polymers, and microRNA in a single integrated delivery system. This composite approach achieves enhanced stability through material synergies while keeping the overall formulation structure manageable and clinically applicable.
Data Source
AI summary
Methods and compositions for treating diabetic retinopathy employ an ophthalmic, topical formulation of micro-RNA 195 packaged in or on a nanoparticle or vesicle.